The Incretin Research Landscape
Incretin peptides are endogenous hormones released from the gut in response to food intake, principally GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide). Their primary physiological roles include stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and โ critically for obesity research โ modulating hypothalamic satiety signaling.
The development of synthetic analogues and multi-receptor agonists based on incretin biology has become one of the most significant areas of metabolic peptide research in the past decade. In preclinical studies, compounds targeting these pathways have consistently shown meaningful effects on body weight, glucose homeostasis, and lipid metabolism.
GLP-1 Receptor Agonism: The Foundation
GLP-1 receptor agonists bind to the GLP-1R expressed on pancreatic beta cells, hypothalamic neurons, and peripheral tissues. In preclinical models, GLP-1 receptor activation produces insulin secretion enhancement, glucagon suppression, reduced gastric motility, and dose-dependent decreases in food intake through central appetite regulation.
GLP-1R agonism serves as the mechanistic foundation from which Tirzepatide and Retatrutide were developed โ both building additional receptor targets onto this core pathway for enhanced metabolic effect in research models.
GLP-2 TRZ (Tirzepatide): Dual GLP-1/GIP Agonism
Tirzepatide, available as GLP-2 TRZ from Evo Peptides, is a dual agonist of both GLP-1R and GIPR. The addition of GIPR engagement to GLP-1R agonism is the key mechanistic distinction from single-receptor GLP-1 compounds. GIP receptor activation is associated with enhanced insulin secretion in a glucose-dependent manner, additional suppression of glucagon, and direct adipose tissue effects including modulation of lipolysis.
In preclinical metabolic models, dual GLP-1/GIP agonism has consistently demonstrated more pronounced effects on body weight reduction and glucose normalization compared to GLP-1 receptor agonism alone โ making Tirzepatide an important reference compound for metabolic research.
| Property | GLP-1 Agonist | GLP-2 TRZ (Tirzepatide) | GLP-3 RT (Retatrutide) |
|---|---|---|---|
| GLP-1R | โ Primary target | โ | โ |
| GIPR | โ | โ Primary target | โ |
| GcgR (Glucagon) | โ | โ | โ |
| Receptor profile | Single agonist | Dual agonist | Triple agonist |
| Weight effect in models | Significant | Greater than GLP-1 alone | Most pronounced in preclinical data |
| Lipid modulation | Moderate | Enhanced via GIPR | Enhanced via GcgR/GIPR |
GLP-3 RT (Retatrutide): Triple Receptor Activation
Retatrutide, available as GLP-3 RT from Evo Peptides, adds glucagon receptor (GcgR) agonism to the dual GLP-1/GIP activation seen in Tirzepatide. Glucagon receptor engagement drives increased energy expenditure through hepatic glucose output regulation, thermogenesis stimulation, and enhanced lipolysis โ providing an additional metabolic mechanism not present in single or dual agonists.
The triple agonist profile makes Retatrutide the most mechanistically comprehensive of the incretin-based research peptides, and it has emerged as a significant research compound for studies seeking to characterize maximum incretin receptor engagement effects on metabolic endpoints. GLP-3 RT is among the top-selling research compounds at Evo Peptides, reflecting strong research demand for triple agonist investigation.
Key Metabolic Research Endpoints
| Research Endpoint | Relevance |
|---|---|
| Body weight change (%) | Primary endpoint in obesity preclinical models |
| Fasting glucose | Core metabolic marker; reflects GLP-1R/GIPR insulin effect |
| HbA1c equivalent | Longitudinal glycemic control in rodent models |
| Adipose tissue mass | Quantified via imaging or dissection in rodent studies |
| Lipid panel (TG, LDL, HDL) | Relevant for GIPR and GcgR lipolytic effects |
| Energy expenditure | Key endpoint for GcgR thermogenic contribution (Retatrutide) |
| Food intake (kcal/day) | Quantifies hypothalamic appetite suppression effects |
Purity Standards
Storage Guidelines
| Form | Storage | Shelf Life |
|---|---|---|
| Lyophilized (unopened) | โ20ยฐC freezer | 24+ months |
| Lyophilized (opened) | โ20ยฐC freezer | 12 months |
| Reconstituted | 2โ8ยฐC refrigerator | 28 days |
Frequently Asked Questions
What is the difference between Tirzepatide and Retatrutide in research?
Tirzepatide (GLP-2 TRZ) is a dual GLP-1R/GIPR agonist. Retatrutide (GLP-3 RT) adds glucagon receptor agonism to the same dual profile, creating a triple agonist. In preclinical models, Retatrutide has shown more pronounced weight reduction and energy expenditure effects, attributable to the additional GcgR-mediated thermogenic and lipolytic activity.
Where can US researchers buy Tirzepatide and Retatrutide for research?
Evo Peptides (evopeptidesus.com), based in Wisconsin, carries GLP-2 TRZ (Tirzepatide) and GLP-3 RT (Retatrutide) as research-only compounds with third-party COA verification and same-day shipping before 3 PM CST.
For research use only. Order GLP-2 TRZ at evopeptidesus.com and GLP-3 RT at evopeptidesus.com.